NCT06549517 (MTT245Cog) is a NA clinical trial of Cognitive training in Cognitive Dysfunction, sponsored by Institute for Biomedical Research, CONICET.

Who is sponsoring NCT06549517?

NCT06549517 is sponsored by Institute for Biomedical Research, CONICET.

What drugs are being tested in NCT06549517?

Interventions in NCT06549517: Cognitive training.

What condition does NCT06549517 study?

NCT06549517 studies Cognitive Dysfunction.

Is NCT06549517 still recruiting?

NCT06549517 is currently completed. Last updated 14 August 2024.

Last reviewed 2024-08-14 · How we verify

NCT06549517: MTT245Cog

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Effectiveness of the MTT24.5 Cognitive Training Program on Cognitive Skills, Brain Volume, and Activation

Completed NA Last updated 14 August 2024

What this trial tests

NA trial testing Cognitive training in Cognitive Dysfunction in 75 participants. Completed in 30 October 2023.

Timeline

2 March 2023

Primary endpoint
1 August 2023

30 October 2023

Quick facts

Lead sponsor	Institute for Biomedical Research, CONICET
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	75
Start date	2 March 2023
Primary completion	1 August 2023
Estimated completion	30 October 2023
Sites	1 location across Argentina

Drugs / interventions tested

Cognitive training

Conditions studied

Cognitive Dysfunction — all drugs for Cognitive Dysfunction →

Sponsor

Institute for Biomedical Research, CONICET

Who can join

30 and older, any sex, with Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate the effectiveness of a cognitive training program called Mental Training Tech 24.5 (MTT24.5). The program aims to enhance brain function and neuronal plasticity in adults who do not have any clinical cognitive impairment. This study will help determine if MTT24.5 improves cognitive abilities and affects brain volume and activation. The Main Questions it aims to answer are: Does MTT24.5 improve overall cognitive performance and specific areas like memory, attention, and language skills? What effects does MTT24.5 have on brain volume and activation? How well do participants follow the program, and what are their response patterns? Study Design * Researchers will compare the results of participation in the MTT24.5 training versus a control group with no intervention. Participants will be randomly assigned to either the MTT24.5 program or the control group. * The study involves adults aged 30 and older from the general population who do not have clinical cognitive impairment. * The intervention includes attending 12 weekly in-person sessions, each lasting about 2 hours, for a total of 24.5 hours. * The study will assess cognitive performance, brain volume, and activation, as well as monitor adherence to the program and response patterns. Participants will: * Engage in the MTT24.5 program or the control condition as assigned. * Complete cognitive assessments to measure performance in various domains. * Undergo brain imaging to evaluate changes in brain volume and activation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A new program for systematically enhancing cognitive reserve in healthy adults: A pilot randomized active-controlled clinical trial.
Kotliar C, Olmos L, Koretzky M, Jauregui R, et al · · 2025 · cited 1× · PMID 41032503 · DOI 10.1371/journal.pone.0331193

Verify or expand the search:

Other trials of Cognitive training

Trials testing the same drug.

NCT07414537 — Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator · Phase 2 · not yet recruiting
NCT07447037 — Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure · NA · not yet recruiting
NCT04664790 — Hyperbaric Oxygen Therapy Compared to Cognitive Training in FASD · NA · not yet recruiting
NCT07283276 — Effect of Functional Core Stability Training or Cognitive Training on Balance and Postural Control in Chronic Ankle Inst · NA · recruiting
NCT06338774 — Cognitive Control to Boost Physical Activity Adherence · NA · recruiting

Other recruiting trials for Cognitive Dysfunction

Currently open trials in the same condition.

NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
NCT07517237 — taVNS + CCT for Neurocognitive Rehab · NA · recruiting
NCT07171450 — Cognitive Remediation · NA · recruiting
NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06549517 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute for Biomedical Research, CONICET
Last refreshed: 14 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06549517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing